8 Sep 2010 10:24
8 September 2010
e-Therapeutics plc
("e-Therapeutics" or the "Company")
Annual General Meeting Statement
e-Therapeutics plc, the drug discovery and development company, today announces that, at its Annual General Meeting ("AGM") which was held earlier today, all resolutions put to shareholders were duly passed.
Dr Royston Drucker notified the Board that he will today step down from his position as Chief Medical Officer and from the Board of e-Therapeutics due to health reasons. Steve Self is directing all clinical and preclinical development at e-Therapeutics.
At today's AGM, Malcolm Young, e-Therapeutics' Chief Executive Officer, gave the following statement: "We remain focused on the progression of our drug development programmes. Each addresses important market sectors and unmet medical needs, and preparations to advance our clinical programmes are well underway. Our network pharmacology platform continues to demonstrate high productivity and effective de-risking of bioactive molecules, and we look forward to reporting further progress on the new development candidates this adds to our portfolio, and on the continuing development of interest in this science from pharmaceutical partners.
"It is with regret that Roy is stepping down from the Board and, on behalf of everyone at e-Therapeutics, I would like to thank him for his many constructive contributions to the Company. Steve Self has taken over direction of development at the Company, and we are very grateful to him for bringing his unmatched experience to bear on our programmes."
For more information, please contact:
e-Therapeutics plc
Malcolm Young / John Cordiner
Tel: +44 (0) 191 233 1317
E-mail: malcolm@etherapeutics.co.uk
www.etherapeutics.co.uk
Panmure Gordon (UK) Limited
Andrew Burnett / Aubrey Powell
Tel: +44 (0) 20 7459 3600
www.panmuregordon.com
M:Communications
Mary-Jane Elliott / Emma Thompson
Tel: +44 (0) 20 7920 2330
E-mail: healthcare@mcomgroup.com
www.mcomgroup.com
Notes for editors
About e-Therapeutics
e-Therapeutics is a pioneering network pharmacology company focused on drug discovery and development. e-Therapeutics has a broad clinical pipeline that combines mid- and late-stage pharmaceutical products with earlier stage opportunities, all addressing important market sectors and unmet medical needs. e-Therapeutics' novel discovery and de-risking platform is becoming increasingly well validated, demonstrating far higher productivity than conventional platforms and enabling e-Therapeutics to continue to deliver many valuable new development candidates to its portfolio. e-Therapeutics, which has a strong IP position, is focused on the progression of its drug development programmes, securing strategically important licensing partners and broadening its pipeline with new, de-risked drug candidates.
Network pharmacology is a new paradigm in drug discovery. It is based on a more realistic view of the interaction of drug molecules with networks of proteins inside and between cells. It uses information on these protein networks in diseased and normal cells; information about the full range of proteins that are affected by the presence of a molecule; and a validated computational technique to determine the impact of these interactions on these cells. This approach is now a feature of several of the major pharmaceutical companies' internal activities and interest in this area is growing rapidly. e-Therapeutics is based in the UK. For more information, please visit http://www.etherapeutics.co.uk.